Stay updated on Cevostamab Safety & Activity in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Cevostamab Safety & Activity in Multiple Myeloma Clinical Trial page.

Latest updates to the Cevostamab Safety & Activity in Multiple Myeloma Clinical Trial page
- Check6 days agoChange DetectedThe page history now includes a new revision entry Revision: v3.3.2, replacing v3.3.1, which is a minor metadata update to the revision list. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check13 days agoChange DetectedThe record history shows a new revision (v3.3.1) and removal of a previous revision (v3.2.0), which are version-tracking updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRemoved a government funding status notice across the page, with no impact on study data, eligibility, or navigation. The layout remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe new screenshot shows an updated version of the record with changes to the study status and recruitment details for CAMMA 1 (NCT04910568). The layout remains similar, but the updated entries reflect progress in the trial.SummaryDifference0.1%

- Check56 days agoChange DetectedUpdate adds a new study status section with contacts/locations and a new date entry, while removing an older dated item to reflect current information.SummaryDifference0.7%

- Check63 days agoChange Detected- Added a government funding notice and operating status guidance, plus a pointer to cc.nih.gov; - Bumped version from v3.1.0 to v3.2.0.SummaryDifference9%

Stay in the know with updates to Cevostamab Safety & Activity in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cevostamab Safety & Activity in Multiple Myeloma Clinical Trial page.